Aug 28, 2023
UnitedHealthcare has added the following specialty medical drug to its Review at Launch Medication List:
- Rystiggo® (rozanollxlzumab-noll) for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive
Providers are strongly encouraged to seek a pre-determination on new-to-market medications that are on the Review at Launch list, in order to ensure coverage. Please be aware if a pre-determination is not requested, UnitedHealthcare may later deny the service or item as not medically appropriate or not covered.
Contact your Amwins Connect Regional Sales Manager for further information.
